23andMe remains optimistic despite FDA issues: ‘We are not going anywhere’ (exclusive)

[NewsCopy]

In the first in-depth interview with the press since the FDA's letter, 23andMe spokesperson Catherine Afarian told VentureBeat that the company's decision will shape the entire genetics industry, which she believes is the "future of medicine."

The rest of the story